Repligen
RGEN
$136.99
-5.84%
Repligen is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, vaccines, and cell and gene therapies. It holds a distinct competitive position as a specialized supplier to biopharmaceutical manufacturers and CDMOs, with a diversified product portfolio spanning filtration, chromatography, proteins, and process analytics. The current investor narrative centers on Repligen's recovery from a post-pandemic demand normalization, with recent quarterly revenue growth of 14.8% year-over-year signaling a rebound in bioprocessing end-markets. Attention is also focused on the company's margin trajectory and the potential for M&A in the life sciences tools sector, as highlighted by Merck KGaA's acquisition offer for peer Bio-Techne.…
RGEN
Repligen
$136.99
Related headlines
Investment Opinion: Should I buy RGEN Today?
Rating: Buy. Repligen is a cyclical growth stock in the early stages of a demand recovery, supported by accelerating revenue, improving margins, and strong analyst conviction. The consensus Strong Buy rating and average target of $178.05 provide a 20.9% upside, making the risk/reward attractive for investors with a 12-month horizon.
Supporting evidence: (1) Revenue growth accelerated to 14.8% YoY in Q1 2026, signaling a cyclical inflection. (2) Gross margin improved to 50.7% from 47.2% sequentially, showing operating leverage. (3) Forward P/E of 57.7x, while high, is justified by expected EPS growth of ~150% (from $0.15 to $0.38 estimated). (4) Free cash flow of $104.1M TTM provides a cushion for investment. (5) Analyst average target implies 20.9% upside, with a high target of $220 offering 49.4% upside.
Risks & Conditions: The biggest risks are a deceleration in revenue growth below 10% or a failure to expand net margins beyond 5%. If growth disappoints, the forward P/E could contract, leading to a downgrade to Hold. Conversely, if revenue growth sustains above 15% and margins reach 10% net, the stock could re-rate higher, supporting an upgrade. Relative to its history and peers, RGEN is overvalued on trailing earnings but fairly valued on forward earnings if the recovery materializes. The valuation verdict: fairly valued on a forward basis, but overvalued on trailing metrics, making it a buy only for those confident in the recovery.
Sign up to view all
RGEN 12-Month Price Forecast
Repligen is positioned for a cyclical recovery in bioprocessing, with Q1 2026 revenue growth of 14.8% marking a clear inflection. The stock's forward P/E of 57.7x is high but justified by expected earnings growth, and the Strong Buy consensus supports the thesis. However, the trailing P/E of 188.3x and low net margin of 4.3% highlight execution risk. The base case of 12-15% growth and gradual margin expansion is most likely, yielding a 12-month target of $160-178. An upgrade to higher conviction would require sustained revenue growth above 15% and margin expansion above 50% gross. A downgrade would follow if growth decelerates below 8% or margins contract.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Repligen's 12-month outlook, with a consensus price target around $178.05 and implied upside of +30.0% versus the current price.
Average Target
$178.05
0 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$142 - $220
Analyst target range
Repligen is covered by 20 analysts, with a consensus recommendation of 'Strong Buy' (mean score 1.45 on a 1-5 scale). The average target price is $178.05, implying 20.9% upside from the current price of $147.25. The distribution shows 1 Hold (from Canaccord Genuity) and the rest Buy or Outperform, indicating strong bullish sentiment. The target range spans from a low of $142.00 to a high of $220.00. The high target of $220 assumes a full recovery to prior peak multiples and accelerating growth, while the low target of $142 suggests only modest upside and potential for margin compression or slower demand. Recent ratings actions include Benchmark upgrading from Hold to Buy on July 7, 2026, and consistent Outperform ratings from Evercore ISI and Barclays, reinforcing the positive outlook. The wide spread between low and high targets ($78) reflects uncertainty about the pace of recovery, but the overall consensus is firmly bullish.
Drowning in data?
Find the real signal!
Bulls vs Bears: RGEN Investment Factors
Repligen presents a compelling cyclical recovery story with accelerating revenue growth, improving margins, and strong analyst support. The bull case is anchored by a 14.8% YoY revenue rebound, a Strong Buy consensus with 20.9% upside to the average target, and a healthy balance sheet that provides financial flexibility. However, the bear case highlights extreme trailing valuation (188.3x P/E), low profitability (4.3% net margin), and execution risk in sustaining growth. The single most important tension is whether the revenue acceleration is sustainable—if growth continues at 15%+, the forward P/E of 57.7x becomes justified; if it decelerates, the stock could re-rate sharply lower. Currently, the evidence slightly favors the bulls given the inflection in fundamentals and favorable analyst sentiment, but the valuation leaves little margin for error.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue grew 14.8% YoY to $194.3M, accelerating from 5.7% in the prior quarter. This marks a clear inflection from the post-pandemic destocking cycle, signaling a recovery in bioprocessing end-markets.
- Strong Analyst Consensus: 20 analysts rate RGEN a Strong Buy with a mean score of 1.45/5. The average price target of $178.05 implies 20.9% upside from $147.25, and the high target of $220 suggests 49.4% potential return.
- Improving Margins: Gross margin improved to 50.7% in Q1 2026 from 47.2% in Q4 2025, and operating margin rose to 9.3% from 3.9% a year ago. This demonstrates operating leverage as revenue scales.
- Healthy Balance Sheet: With $582.7M cash, debt-to-equity of 0.33, and current ratio of 8.4, Repligen has ample liquidity. Free cash flow of $23.3M in Q1 and $104.1M TTM supports internal investment and M&A optionality.
Bearish
- Extreme Trailing P/E: Trailing P/E of 188.3x is near the high end of its historical range (45x-300x). This leaves no room for earnings disappointment; any miss could trigger severe multiple compression.
- Low Net Margin: Net margin of 4.3% in Q1 2026, though improved from 3.4% a year ago, remains well below the 2022 peak of ~20%. High operating expenses (SGA 39% of revenue) pressure profitability.
- Cyclical Demand Recovery Risk: The 14.8% growth follows a period of destocking. If bioprocessing demand normalizes slower than expected, revenue growth could decelerate, undermining the forward P/E of 57.7x.
- Low ROE and ROA: ROE of 2.3% and ROA of 1.2% are well below cost of equity. This suggests capital is not being deployed efficiently, and the high equity base from prior raises dilutes returns.
RGEN Technical Analysis
Repligen's stock is in a recovery uptrend after a prolonged decline, with a 1-year price change of +18.7% as of July 17, 2026. The current price of $147.25 sits at 56% of its 52-week range ($100.99 to $175.77), indicating room for further upside but still below the highs. This positioning suggests the stock is in a mid-cycle recovery phase, not yet overextended, but with momentum building. The 1-month price change of +10.3% and 3-month change of +12.2% show accelerating short-term momentum, diverging from the 6-month decline of -9.1%. This divergence suggests the stock may have bottomed in May 2026 near $102.87 and is now in a reversal pattern, supported by a 1-month relative strength of +9.9% versus the S&P 500. The 52-week low of $100.99 provides strong support, while the 52-week high of $175.77 is the key resistance. A breakout above $175.77 would signal a full recovery and potential new highs, while a breakdown below $100.99 would indicate a continuation of the downtrend. With a beta of 1.06, Repligen's volatility is roughly in line with the market, meaning it offers no significant risk premium or cushion relative to the S&P 500.
Beta
1.06
1.06x market volatility
Max Drawdown
-40.3%
Largest decline past year
52-Week Range
$101-$176
Price range past year
Annual Return
+19.3%
Cumulative gain past year
| Period | RGEN Return | S&P 500 |
|---|---|---|
| 1m | +3.8% | +0.2% |
| 3m | +10.1% | +5.2% |
| 6m | -18.4% | +8.6% |
| 1y | +19.3% | +19.0% |
| ytd | -16.6% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RGEN Fundamental Analysis
Revenue in the most recent quarter (Q1 2026) was $194.3 million, up 14.8% year-over-year from $169.2 million in Q1 2025, accelerating from the prior quarter's 5.7% growth. The trailing twelve-month revenue reached approximately $763 million, with sequential improvement from $182.4 million in Q2 2025 to $197.9 million in Q4 2025. The growth is broad-based, with product revenue of $194.2 million dominating and royalty revenue of $44,000 minimal. This acceleration suggests the bioprocessing end-market is recovering from destocking headwinds, supporting the investment case for a cyclical rebound. Net income in Q1 2026 was $8.3 million, with a net margin of 4.3%, up from 3.4% in Q1 2025 but down from 8.2% in Q2 2025. Gross margin improved to 50.7% from 47.2% in Q4 2025, indicating better product mix or cost control. Operating margin was 9.3%, up from 3.9% a year ago, showing operating leverage as revenue grows. However, margins remain below the 2022 peaks (gross margin ~58%), suggesting room for further expansion as volumes increase. Repligen has a strong balance sheet with $582.7 million in cash, a debt-to-equity ratio of 0.33, and a current ratio of 8.4. Free cash flow was $23.3 million in Q1 2026, and trailing twelve-month FCF was $104.1 million, providing ample liquidity for internal investments. ROE is low at 2.3%, reflecting the high equity base from prior capital raises, but the company generates sufficient cash to fund operations without external financing.
Quarterly Revenue
$194255000.0B
2026-03
Revenue YoY Growth
+14.8%
YoY Comparison
Gross Margin
50.7%
Latest Quarter
Free Cash Flow
$104112000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RGEN Overvalued?
Since net income is positive ($8.3 million), the primary valuation metric is the P/E ratio. The trailing P/E is 188.3x, while the forward P/E is 57.7x, implying the market expects significant earnings growth in the next year. The wide gap between trailing and forward P/E reflects the cyclical trough in earnings and the anticipated recovery. The P/S ratio of 12.5x and EV/Sales of 10.9x provide alternative perspectives. Compared to the Medical Instruments & Supplies industry average P/S of approximately 4.5x (estimated), Repligen trades at a 178% premium, reflecting its higher growth profile and specialized market position. The premium is partially justified by its 14.8% revenue growth versus industry averages of 5-8%, but the P/E premium is extreme due to depressed earnings. Historically, Repligen's trailing P/E has ranged from 45x to over 300x in the past five years. The current 188x is near the higher end of its historical band, suggesting the market is pricing in optimistic future earnings. However, the forward P/E of 57.7x is closer to historical mid-range, indicating that if earnings materialize as expected, the valuation could normalize.
PE
188.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 45x~196x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
56.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Repligen's trailing P/E of 188.3x is extremely elevated, implying the market expects a dramatic earnings recovery. If revenue growth decelerates or margins fail to expand, the stock could suffer severe multiple compression. Net margin of 4.3% is low for a life sciences tools company, and operating expenses (SGA at 39% of revenue) remain high. The company has $582.7M in cash but low ROE (2.3%) suggests capital is not being deployed efficiently. Free cash flow of $104.1M TTM is positive but modest relative to the $9.2B market cap.
Market & Competitive Risks: Repligen trades at a P/S of 12.5x versus the industry average of ~4.5x, a 178% premium that must be justified by sustained above-average growth. The stock's beta of 1.06 indicates roughly market-level volatility, offering no downside protection. The recent Merck KGaA bid for Bio-Techne highlights M&A interest but also raises the risk that Repligen could be left behind if it fails to execute. Regulatory changes in biologic drug approvals or a shift to alternative manufacturing technologies could disrupt demand.
Worst-Case Scenario: If the bioprocessing recovery stalls, revenue growth could fall below 5%, margins could compress further, and the forward P/E of 57.7x could contract to 30x. In this scenario, the stock could decline to the 52-week low of $100.99, representing a 31.4% loss from the current price of $147.25. This aligns with the analyst low target of $142, which implies only a 3.6% downside, but a more severe downturn could match the historical max drawdown of -40.3%, bringing the stock to ~$88.
FAQ
The key risks are: (1) Valuation risk: trailing P/E of 188.3x leaves no room for error—any earnings miss could trigger a sharp de-rating. (2) Execution risk: net margin of 4.3% is low, and if revenue growth decelerates below 10%, margins may not expand as expected. (3) Cyclical risk: the bioprocessing recovery may be uneven; a renewed downturn could push the stock to the 52-week low of $100.99. (4) Competitive risk: larger players like Danaher or Thermo Fisher could introduce competing products, pressuring market share. The most severe risk is a growth stall leading to a 31% decline from current levels.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock trading between $160 and $178, driven by 12-15% revenue growth and gradual margin expansion. The bull case (30% probability) targets $178-$220 if growth accelerates above 20% and M&A speculation emerges. The bear case (20% probability) sees a decline to $101-$142 if the recovery stalls. The most likely scenario is the base case, with the stock reaching the analyst average target of $178.05, implying 20.9% upside from the current price of $147.25.
RGEN is overvalued on trailing earnings (P/E 188.3x) but fairly valued on forward earnings (P/E 57.7x) if the expected earnings recovery materializes. The P/S ratio of 12.5x is a 178% premium to the industry average of ~4.5x, reflecting its higher growth profile. Historically, the trailing P/E has ranged from 45x to 300x, so the current level is near the high end. The market is pricing in a strong rebound in earnings, which is plausible given the 14.8% revenue growth and margin improvement. If earnings meet estimates, the forward P/E of 57.7x is reasonable; if not, the stock is overvalued.
RGEN is a good buy for investors with a 12-month horizon who believe the bioprocessing recovery is sustainable. The stock offers 20.9% upside to the analyst average target of $178.05, supported by accelerating revenue growth (14.8% YoY) and improving margins. However, the trailing P/E of 188.3x is extremely high, so the investment is contingent on continued growth. For risk-averse investors, the low target of $142 suggests only 3.6% downside, but the bear case could see a 31% decline to the 52-week low of $100.99 if the recovery stalls. Overall, it's a buy for those with a higher risk tolerance and conviction in the cyclical upturn.
RGEN is best suited for a medium-term investment of 12-24 months, aligning with the expected cyclical recovery in bioprocessing. The stock's beta of 1.06 indicates market-level volatility, making it less suitable for short-term trading due to potential sharp swings. It pays no dividend, so income investors should look elsewhere. For long-term investors (5+ years), the company's position in biologic drug manufacturing provides secular tailwinds, but the current high valuation suggests better entry points may emerge. A minimum holding period of 12 months is recommended to allow the recovery thesis to play out.
